HRNR and hepatocellular carcinoma: found that among cancer patients receiving anti-PD-L1 therapy, those with hepatocellular carcinoma (HCC) who had double-high expression of HRNR and CircCDYL were associated with elevated levels of CEA, ALT, and AST, as well as larger tumor diameters, compared to the non-double-positive group (31).